Compare PATK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATK | RCUS |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 1994 | 2018 |
| Metric | PATK | RCUS |
|---|---|---|
| Price | $90.66 | $24.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $122.75 | $31.90 |
| AVG Volume (30 Days) | 430.3K | ★ 861.0K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | $29,000,000.00 | ★ $247,000,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $6.51 | $45.62 |
| P/E Ratio | $82.02 | ★ N/A |
| Revenue Growth | ★ 262.50 | N/A |
| 52 Week Low | $83.96 | $7.92 |
| 52 Week High | $148.50 | $28.72 |
| Indicator | PATK | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 47.26 |
| Support Level | $87.53 | $20.20 |
| Resistance Level | $98.39 | $24.33 |
| Average True Range (ATR) | 2.73 | 1.21 |
| MACD | 0.54 | 0.00 |
| Stochastic Oscillator | 27.39 | 35.31 |
Patrick Industries Inc is a component solutions provider for the recreational vehicle (RV), marine, powersports, manufactured housing (MH), and various industrial markets, including single and multi-family housing, hospitality, institutional, and commercial markets. The company operates within two reportable segments, Manufacturing and Distribution. The majority of its revenue is generated from the Manufacturing segment, which offers laminated products utilized to produce furniture, shelving, walls, and countertops; fabricated aluminum products; cabinet products, doors, components, and custom cabinetry; interior passage doors and baggage doors; RV and marine furniture, etc. Geographically, the company mainly operates in the United States, with a small presence in Mexico, China, and Canada.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.